Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL30761717 | 1.00 | NOS1 (0.52) | NOS1DHFR | |
| Bromide SCHEMBL29695506 | 1.00 | NOS1 (0.52) | NOS1DHFR | |
| Bromide SCHEMBL29515501 | 1.00 | NOS1 (0.52) | NOS1DHFR | |
| Bromide SCHEMBL1116048 | 1.00 | NOS1 (0.52) | NOS1DHFR | |
| SCHEMBL64146 | 0.98 | NOS1 (0.54) | NOS1DHFR | |
| SCHEMBL31143797 | 0.98 | NOS1 (0.54) | NOS1DHFR | |
| SCHEMBL30435493 | 0.98 | NOS1 (0.54) | NOS1DHFR | |
| Hydrochloric Acid SCHEMBL479239 | 0.97 | NOS1 (0.52) | NOS1DHFR | |
| Bromide SCHEMBL28577318 | 0.95 | NOS1 (0.51) | NOS1DHFR | |
| Isopropyl Alcohol SCHEMBL8445236 | 0.91 | NOS1 (0.49) | NOS1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872313-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-16 | — | — | US | disclosed |
| US-11141379-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210077400-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-18 | — | — | US | disclosed |
| US-20190192436-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-06-27 | — | — | US | disclosed |
| US-10201500-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
| EP-2558072-B1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | UNIV WASHINGTON (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9498439-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160279060-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-29 | — | — | US | disclosed |
| US-20130122100-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | THE WASHINGTON UNIVERSITY (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2558072-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | The Washington University (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130674-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | THE WASHINGTON UNIVERSITY (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279060-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | FAP, PNP, TYMP | NOS1 835/4885DHFR 517/4885 |
| US-20130122100-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | PHOSPHO1, PTDSS1, SMPD3 | NOS1 1446/4885DHFR 1486/4885 |
| US-20190192436-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | FAP, PNP, TYMP | NOS1 835/4885DHFR 517/4885 |
| US-11141379-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | NOS1 835/4885DHFR 517/4885 |
| US-20210077400-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | FAP, PNP, TYMP | NOS1 835/4885DHFR 517/4885 |
| US-10201500-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | NOS1 835/4885DHFR 517/4885 |
| US-11872313-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | NOS1 835/4885DHFR 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.